Monoamine Oxidase Inhibitor drugs compared
Compare all 4 Monoamine Oxidase Inhibitor drugs side by side, used for conditions such as parkinson disease, alzheimer disease, attention deficit disorder with hyperactivity. They share one FDA-defined mechanism but differ in approved uses, prescription status, brand-vs-generic options, price, and FDA recall-safety record — which our independent rating scores.
Full ranking · 4 drugs
- 156/100
azilect
Rasagiline Mesylate
- 2New
emsam
Selegiline
- 3New
nardil
Phenelzine Sulfate
- 4New
zelapar
Selegiline Hydrochloride
Frequently asked questions
What is the Monoamine Oxidase Inhibitor drug class?
Monoamine Oxidase Inhibitor is an FDA Established Pharmacologic Class (EPC) — a group of drugs that share a mechanism of action. pharmaranks lists 4 Monoamine Oxidase Inhibitor products, each independently rated.
Are all Monoamine Oxidase Inhibitor drugs the same?
No. Monoamine Oxidase Inhibitor drugs share the same core mechanism — that is why they sit in one FDA class — but they differ in their approved uses, available forms, whether they are prescription or over-the-counter, brand-vs-generic options and price, and their FDA recall-safety record.
What conditions do Monoamine Oxidase Inhibitor drugs treat?
Per NIH RxClass drug-classification data, Monoamine Oxidase Inhibitor drugs are used for conditions including parkinson disease, alzheimer disease, attention deficit disorder with hyperactivity, depressive disorder, schizophrenia.
Sources: the Monoamine Oxidase Inhibitor class definition and its member drugs come from the U.S. NLM RxClass (Established Pharmacologic Class). Ratings are pharmaranks’ independent FDA recall-safety analysis.